These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9072699)

  • 1. Viral load and combination therapy for human immunodeficiency virus.
    Srinivasan V; Beidas SO
    N Engl J Med; 1997 Mar; 336(13):960; author reply 961. PubMed ID: 9072699
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV-1 load quantitation: a 17-year perspective.
    Holodniy M
    J Infect Dis; 2006 Sep; 194 Suppl 1():S38-44. PubMed ID: 16921471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.
    Fialaire P; Payan C; Vitour D; Chennebault JM; Loison J; Pichard E; Lunel F
    J Infect Dis; 1999 Aug; 180(2):574-5. PubMed ID: 10395889
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV-1 viral load in blood and semen plasma of Brazilian patients under antiretroviral therapy.
    Medeiros RP; Munerato P; Diaz RS
    J Clin Virol; 2004 Aug; 30(4):346-7. PubMed ID: 15163426
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiretroviral therapy in human immunodeficiency virus-infected individuals.
    Spooner KM
    Adv Intern Med; 1998; 43():373-402. PubMed ID: 9506188
    [No Abstract]   [Full Text] [Related]  

  • 6. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
    Phillips AN; Staszewski S; Lampe F; Youle MS; Klauke S; Bickel M; Sabin CA; Doerr HW; Johnson MA; Loveday C; Miller V; ;
    J Infect Dis; 2002 Oct; 186(8):1086-91. PubMed ID: 12355358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between caregiver knowledge of antiretroviral therapy regimens and disease parameters among perinatally human immunodeficiency virus-infected children.
    Nicholson O; Mellins C; Dolezal C; Santamaria EK; Brackis-Cott E; Abrams EJ
    Arch Pediatr Adolesc Med; 2006 Dec; 160(12):1307-8. PubMed ID: 17146031
    [No Abstract]   [Full Text] [Related]  

  • 8. Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple.
    Razzolini F; Saladini F; Malincarne L; Vicenti I; Palladino N; Romano L; Francisci D; Zazzi M
    J Clin Microbiol; 2008 Nov; 46(11):3856-9. PubMed ID: 18845824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy.
    Ragni MV; Bontempo FA
    J Infect Dis; 1999 Dec; 180(6):2027-9. PubMed ID: 10558963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral load testing in resource-limited settings.
    Schooley RT
    Clin Infect Dis; 2007 Jan; 44(1):139-40. PubMed ID: 17143830
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantification of human immunodeficiency virus type 1 by reverse transcriptase-coupled polymerase chain reaction.
    Kuritzkes DR
    J Infect Dis; 2004 Dec; 190(11):2047-54. PubMed ID: 15529271
    [No Abstract]   [Full Text] [Related]  

  • 12. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.
    Miller V; Staszewski S; Sabin C; Carlebach A; Rottmann C; Weidmann E; Rabenau H; Hill A; Lepri AC; Phillips AN
    J Infect Dis; 1999 Aug; 180(2):530-3. PubMed ID: 10395876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Questions about results reported with potent antiretroviral therapy for human immunodeficiency virus type 1 infection.
    Papadopulos-Eleopulos E; Turner VF; Papadimitriou JM; Alfonso H; Page B; Causer D
    J Infect Dis; 2000 Apr; 181(4):1518-20. PubMed ID: 10762589
    [No Abstract]   [Full Text] [Related]  

  • 14. [New biological monitoring of HIV infection].
    Morand-Joubert L
    Rev Prat; 1998 Mar; 48(5):472-7. PubMed ID: 9781107
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy.
    Derdeyn CA; Kilby JM; Miralles GD; Li LF; Sfakianos G; Saag MS; Hockett RD; Bucy RP
    J Infect Dis; 1999 Dec; 180(6):1851-62. PubMed ID: 10558941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cervicovaginal human immunodeficiency virus secretion and plasma viral load in human immunodeficiency virus-seropositive women.
    Uvin SC; Caliendo AM
    Obstet Gynecol; 1997 Nov; 90(5):739-43. PubMed ID: 9351756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy.
    Günthard HF; Wong JK; Spina CA; Ignacio C; Kwok S; Christopherson C; Hwang J; Haubrich R; Havlir D; Richman DD
    J Infect Dis; 2000 Feb; 181(2):522-31. PubMed ID: 10669335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876
    [No Abstract]   [Full Text] [Related]  

  • 19. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.
    Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M
    AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591
    [No Abstract]   [Full Text] [Related]  

  • 20. Determinants of virological response to antiretroviral therapy: implications for long-term strategies.
    Deeks SG
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S177-84. PubMed ID: 10860903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.